The clinical trial of STC007 injection of Sunshine Novo’s subsidiary has achieved the expected goal
May 31, 2025
Source: drugdu
89
May 29, Sunshine Novo(688621) issued an announcement that the Phase II clinical trial of STC007 injection independently developed by the company's wholly-owned subsidiary Novo Shengtai for the treatment of moderate to severe pain after abdominal surgery has achieved the expected goals.
The clinical trial involved 156 subjects and mainly evaluated the efficacy, safety and pharmacokinetic characteristics of STC007 injection. The results showed that STC007 injection significantly improved the pain scores of subjects within 0-24 hours after surgery, and performed better than the control group in terms of the amount of rescue treatment drugs used and the time to first rescue treatment.
In terms of safety, the overall safety and tolerability of STC007 injection were good, no new safety signals were found, and no serious adverse events occurred .Due to the high risk of R&D, investors need to make careful decisions.
In the first quarter of 2025, Sunshine Novo achieved revenue of 231 million yuan and net profit attributable to shareholders of the parent company of 29.58 million yuan.
网址：https://finance.eastmoney.com/a/202505293418005736.html
Copyright©2025 Ddu. All rights reserved.
Read more on
- Innovent Biologics’ Suvicitamab is approved for marketing, solving the dilemma in the treatment of platinum-resistant ovarian cancer July 7, 2025
- Everest Medicines’ Next-Generation BTK Inhibitor EVER001 Announces Latest Clinical Results, Continues to Demonstrate Efficacy and Safety July 7, 2025
- Jinsai Pharmaceutical’s Fuxin Qibaimab was approved, reducing the risk of gout recurrence by 87% in half a year July 7, 2025
- LH-1801 project enters Phase III clinical trial July 7, 2025
- The new generation of DNA biosynthesis technology is moving towards industrialization July 7, 2025
your submission has already been received.
OK
Subscribe
Please enter a valid Email address！
Submit
The most relevant industry news & insight will be sent to you every two weeks.
